Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00801931 · ClinicalTrials.gov registry record · Phase 1
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
A Phase 1 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00801931 is a Phase 1 study that was terminated before completion, run by Columbia University. The registered enrollment target is 1 participants.
The verdict
NCT00801931, a Phase 1 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and toxicity and feasibility of double umbilical cord blood transplantation (DUCBT) in patients with selected malignant and non-malignant, and to quantify the percentage and donor sources of mixed donor chimerism following DUCBT in patients with selected malignant and non-malignant disorders.
Interventions
- DRUG Melphalan
- DRUG Busulfan
- DRUG Alemtuzumab
- RADIATION Total Body Irradiation
- DRUG Phenytoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-09-06 |
| Est. Completion | 2009-05-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00801931
The ClinicalTrials.gov registry entry for NCT00801931 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT00801931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00801931 about?
NCT00801931 is a clinical study titled "Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders". The purpose of this study is to determine the safety and toxicity and feasibility of double umbilical cord blood transplantation (DUCBT) in patients with selected malignant and non-malignant, and to quantify the percentage and donor sources of mixed donor chimerism following DUCBT in patients with s...
What is the current status of trial NCT00801931?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2007-09-06. Estimated completion is 2009-05-05.
What interventions are being tested in trial NCT00801931?
The interventions under investigation include: Melphalan (DRUG), Busulfan (DRUG), Alemtuzumab (DRUG), Total Body Irradiation (RADIATION), Phenytoin (DRUG).
Who is sponsoring clinical trial NCT00801931?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.